The Cancer Industry Doesn’t Want a Cure Even if it’s a Pharmaceutical – Video


02-02-2012 12:59 A safe and effective cure for cancer has been discovered with a drug that was once used for unusual metabolic problems. Yet, the cancer industry shows no interest with following up on dichloroacetate (DCA) research from University of Alberta in Edmonton, Canada, reported in 2007. That’s because DCA is no longer patented. That research also confirmed cancer as a metabolic malfunction, not a weird mutation of cells often explained away as a genetic issue. But the medical mafia doesn’t want you to hear about it. But it confirms what most alternative cancer therapists already know. Since Nixon declared the “war on cancer” in the 1970s, the cancer industry has succeeded with raising money for researching very expensive chemo substances at $50000 to $100000 per round or more for toxic therapies that rarely work. Chemo drugs usually lead to demanding more business with drugs to ease terrible side effects (www.naturalnews.com Meanwhile, more are getting cancer and more are dying from it, mostly because of the toxic treatments. Explaining DCA research results Evangelos Michelakis and the Alberta University research team tested DCA on human cancer cells outside the body and in cancerous mice with profound success. DCA was once used for unusual metabolic disorders. The worst side effects, which rarely occur, include some numbness and an affected gait. The mice were fed DCA in water, and in weeks they had remarkable tumor shrinkage. This indicates DCA can be taken orally. DCA works

Read more here:
The Cancer Industry Doesn’t Want a Cure Even if it’s a Pharmaceutical – Video

Posted in Cell Medicine | Tagged , , , , , , , | Comments Off

Biology at Webster University – Video


03-08-2011 09:09 Sophomores Kevin Chau and Lisa Adden describe the advantages of studying biology at Webster University in St. Louis, Missouri.

See the rest here:
Biology at Webster University – Video

Posted in Biology | Tagged , , , , , , , , , , | Comments Off

Report: CMU biology department sees growth, chairman believes med school had impact

The chairman also said the department endorsed a vote of no confidence in the president and provost.

See the article here:
Report: CMU biology department sees growth, chairman believes med school had impact

Posted in Biology | Tagged , , , , , , , | Comments Off

Signal Genetics to Buy ChipDx, Gaining Cancer Test Pipeline, Bioinformatics Resources

Full-text access for premium subscribers only. Existing premium subscribers login here . New to GenomeWeb? Register quickly here . Genome Technology's Tracy Vence interviewed Sandra Porter , president of Digital World Biology, and Kristi Holmes , a bioinformaticist at the Becker Medical Library, Washington University School of Medicine at ScieneOnline2012.

See the article here:
Signal Genetics to Buy ChipDx, Gaining Cancer Test Pipeline, Bioinformatics Resources

Posted in BioInformatics | Tagged , , , , , , , , | Comments Off

In Print: January's Bioinformatics Papers of note

Full-text access for premium subscribers only. Existing premium subscribers login here . New to GenomeWeb? Register quickly here . Genome Technology's Tracy Vence interviewed Sandra Porter , president of Digital World Biology, and Kristi Holmes , a bioinformaticist at the Becker Medical Library, Washington University School of Medicine at ScieneOnline2012.

Follow this link:
In Print: January's Bioinformatics Papers of note

Posted in BioInformatics | Tagged , , , , , , , , | Comments Off

Bioinformatics Startup Scale Genomics Touts Flexibility as Key Differentiator of Cloud Platform

Life Technologies this week named Alan Sachs as head of global research and development and Ronnie Andrews as president of medical sciences.

Sachs was previously the vice president of exploratory and translational sciences for Merck Research Laboratories, where he spent 10 years in various leadership roles, Life Tech said. Prior to that Sachs served an associate professor of biochemistry and molecular biology at the University of California, Berkeley, and as a Whitehead fellow at the Whitehead Institute for Biomedical Research.

Andrews joins Life Tech from GE Molecular Diagnostics, where he served as a segment leader following GE's 2010 acquisition of Clarient, where Andrews was CEO. Andrews has also held executive positions with Abbott Diagnostics, Roche Diagnostics, and Immucor.

Stephen O'Brien has left the National Cancer Institute's Laboratory of Genomic Diversity after 25 years to help launch a genome bioinformatics program at St. Petersburg University in Russia. O'Brien received a $5 million grant from the Russian Ministry of Education and Science last year under a program that aims to lure big-name researchers to Russia. Over the coming three years, O'Brien will spend at least four months per year in Russia working at the center, which is scheduled to open in May.

Saladax Biomedical said today that President and CEO Edward Erickson has resigned due to personal and family reasons, and that he will be replaced by Kevin Harter on an interim basis. Erickson will remain a member of the company's board of directors. Harter is a co-founder and senior VP of the Life Sciences Greenhouse, and he has served as executive chairman at Saladax.

The rest is here:
Bioinformatics Startup Scale Genomics Touts Flexibility as Key Differentiator of Cloud Platform

Posted in BioInformatics | Tagged , , , , , , , , , , , , | Comments Off

Essex Angel Capital Inc. Announces: Wellness Indicators, Inc. Founder Is Guest Speaker at National Labor Management …

WINDSOR, ONTARIO– – Essex Angel Capital Inc. is pleased to announce that Denis Callewaert, Founder and Chief Science Officer of Wellness Indicators, Inc. , one of the companies in the Essex portfolio, will be a guest speaker at the National Labor Management Conference in Hollywood, FL, February 16-21, …

Originally posted here:
Essex Angel Capital Inc. Announces: Wellness Indicators, Inc. Founder Is Guest Speaker at National Labor Management …

Posted in Biochemistry | Tagged , , , , , , , , , , , , , | Comments Off

The anatomy of a fabricated statement

IN September of 2006, Detective Sergeant Michael Sirjue was faced with a scenario that most homicide investigators across the island face: A murder, a hesitant eyewitness, and the possibility that the suspects may not be brought to justice.

Here is the original post:
The anatomy of a fabricated statement

Posted in Anatomy | Tagged , , , , , , , , | Comments Off

Is 'Grey's Anatomy' Sending Katherine Heigl A Message?

The Feb. 2 installment of “Grey's Anatomy” — the “If/Then” alternate reality episode — welcomed back a few familiar faces and dearly departed friends, but it also gave the giant middle finger to a few others.

In an episode where anything was possible (Meredith wearing pink! Addison pregnant!), the only thing scoffed at more than George O'Malley (a.k.a. “007″ license to kill) was “crazy” Izzie, their old pal who lost her job for sleeping with a patient and stealing a heart for him. Sound familiar?

When I visited the “Grey's Anatomy” set recently while they filmed their upcoming “Private Practice” crossover, Ellen Pompeo was very frank about who, if anyone, she'd welcome back to the show with open arms. And even with Katherine Heigl's constant media pleas lately to return to the show, her name never came up.

If you could have any one character back on the show, alive or dead, who would you like to return?
“Well, I have to say, I do love Kate Burton. She's a tremendous actress, and any minute I get to work with her is fun. I love having Kate. I was so sad when our relationship on the show ended — when she died and I couldn't have her anymore — because I thought that was such an interesting dynamic, and it's so fun to play. So I was glad to have a second crack at that.”

Yes, it could be that Pompeo name-dropped the one woman who did come back for that very special episode — Kate Burton as Meredith's mom Ellis Grey — because it was fresh on her brain. Or it could be that the cast of “Grey's” is sending Heigl a message: You had your chance. Thanks, but no thanks.

What do you think: Should they let Heigl return to wrap up Izzie's story once and for all?

Go here to read the rest:
Is 'Grey's Anatomy' Sending Katherine Heigl A Message?

Posted in Anatomy | Tagged , , , , , , , , | Comments Off

Anatomy OF AN ELITE QB

INDIANAPOLIS — He was always being compared to someone. That’s what happens when you’re the youngest son of a great quarterback and the baby brother of an even better one. It wasn’t until he compared himself to Tom Brady, though, that people began taking Eli Manning seriously.

That was in August, when Manning was asked whether he considered himself an “elite” quarterback like Brady. Manning said simply that he belonged “in that class.” But in New York, where blowing things out of proportion is practically a civic duty, even most Giants fans regarded it as heresy at the time. By Sunday night, it could be fact.

So ready or not, it’s time for the “other” Manning vs. Brady, Part II. Both are back in Sunday’s Super Bowl, four years after they first clashed, each with plenty still to prove.

“It’s not my job to list quarterbacks,” Manning said this week. “He’s obviously a future Hall of Famer.”

Yet Brady has looked like anything but that in his last 11 postseason games, posting a 6-5 mark, including a 2008 Super Bowl loss to Manning and the Giants. For most of those, he’s been knocked around a lot, picked off more than usual and tagged with a quarterback rating that wouldn’t qualify as a low-grade fever. Measured against the nearly impossible standard that Brady set at the start of his career — 10 straight postseason wins and three Super Bowl titles — merely average would be a more accurate description.

Perception still lags behind that reality, in no small part because everything else about Brady still screams “winner.” Now 34, he is still boyishly handsome, still as charming as ever, still the most sought-after endorser and the one athlete even his peers would kill to be. He returns home every night with two sons to look after — and a supermodel wife.

Yet those who know Brady have long marveled at how well he hides a competitive streak even Michael Jordan would admire. And despite outward appearances, they wonder how Brady is managing it now, coming up short of his ultimate goal every season since 2005, after winning three in four years. Patriots backup quarterback Brian Hoyer ticked off a laundry list of things he’s been studying in the three seasons he’s sat behind Brady: mechanics, poise and attention to detail, even the tone of voice he uses to command respect in a huddle.

But the one thing Hoyer worries will never rub off is Brady’s raw desire.

“At the end of just about every practice, I run out there and try to get the last few reps with the first team,” Hoyer said.

“And just about every practice, whether it’s a steamy day in training camp or a short walk-through after watching film, he runs out there, grabs me and says something like, ‘Get the hell out of here!’ — only it’s not always even that nice. …

“Everybody outside this team looks at him and thinks ‘pretty-boy QB.’ But Tom doesn’t try hiding it from us,” Hoyer said. “He’s a killer.”

Manning, too, shares that trait and has been honing it for nearly as long. Like Brady, he was the baby of the family and quickly learned he could get his way by being demanding one moment and wheedling the next. Like his father, Archie, the longtime Saints quarterback, and older brother Peyton, who almost single-handedly vaulted the Colts to the top of the NFL heap, Eli burned to win all the time, too. But he wasn’t above playing the trump card — his mother, Olivia.

“He would pin me down,” Eli, now 31, recalled growing up with Peyton, “and take his knuckles and knock on my chest and make me name the 12 schools in the SEC. I didn’t know them all at the time, but I quickly learned them. … I don’t suggest anyone else try it out, but it definitely made me learn the schools of the SEC. Once I figured those out, he moved on.

“There were 28 teams in the NFL at that point, so all teams in the NFL. I had to get my studying on for that. Then once I figured that out, the one I never got was the 10 brands of cigarettes. When he really wanted to torture me and knew I had no shot of ever getting it,” he added, “that’s when I just started screaming for my mom or dad to come save me.”

Contrast that with the story Brady told about growing up with three older sisters.

“I didn’t have to share clothes. I didn’t have to fight over the bathroom. They were pretty easy on me. They dressed me up a few times in their clothes and painted my nails once, but it was nice,” Brady said without a shred of embarrassment. “They’d bring all of their girlfriends over to the house. It was pretty cool.”

Manning was drafted No. 1 overall in 2004 by the Chargers. They promptly traded him to the Giants for quarterback Philip Rivers, the No. 4 pick, a swap that rumor had it was engineered by Archie. Either way, Manning arrived to much fanfare and not a little resentment.

Kurt Warner, a Super Bowl winner in St. Louis a few years earlier, was New York’s starter at the time, but even he didn’t envy Manning the situation he walked into.

“He’s got the name to live up to, the way he wound up there, and he’s in New York, where you can be the best thing since sliced bread the first quarter, and the worst thing to ever walk the earth by the second,” said Warner, who started that season 5-4 before giving way to Manning.

See the original post here:
Anatomy OF AN ELITE QB

Posted in Anatomy | Tagged , , , , , , , , , , , , , | Comments Off

Anatomy of a picture: The Great Gatsby

The true star of Baz Luhrmann's 3D film could well be DiCaprio's hair. But what else does this still tell us? 1) Stereoscopic hair Baz Luhrmann may have had the novel's kinetic climax in mind when he decided to film The Great Gatsby in 3D, but the star of the show will undeniably be Leonardo DiCaprio 's hair. Imagine it flicking and swishing at you in three dimensions. Part L'Oréal ad and part …

Read more here:
Anatomy of a picture: The Great Gatsby

Posted in Anatomy | Tagged , , , , , , , , , , | Comments Off

'Anatomy of a Murder' star Gazzara dies

The actor died Friday of pancreatic cancer, The New York Times reported. The star of films and plays such as “Anatomy of a Murder” and “Cat on a Hot Tin Roof” was 81.

Read more:
'Anatomy of a Murder' star Gazzara dies

Posted in Anatomy | Tagged , , , , , | Comments Off

‘Grey’s Anatomy’ alt-reality episode: Where does it rank among the classics?

Image Credit: Vivian Zink/ABC

I don’t think it’d be inaccurate to say that last night’s alternate reality episode of Grey’s Anatomy was a strong effort.

There was enough activity that paralleled our normal reality to make it feel familiar (Callie had eyes for Arizona, Meredith and Derek were oddly connected), yet enough deviation to make it feel exciting, new, and just a little funny. (Meredith was engaged to ALEX?!) And who wouldn’t appreciate the macabre humor that hung over the hour? (Percy: “Someone shoot me now.” HA!)

Still, when compared to some of the great alternate reality episodes ever produced, where, exactly, does it rank, readers?

I guess the answer depends on what you seek from alternate reality episodes.

Immediately, I found myself comparing last night’s episode to that one episode of Smallville (Don’t look at me that way. I’m a CW girl; what can I say?) that showed what life would be like if Superman didn’t exist. The lessons in that one were a bit more overt than those in Grey’s. But I appreciated the value put in the idea — it was the one thing I felt that was missing from the Grey’s episode. Even after watching it, I’m not sure why we had to bring it up at all. (Some might say it was to lighten the air after the intense episode that came before the one we just watched, but I don’t think that’s excuse enough to remove us so drastically from the story.)

That small gripe aside, I enjoyed it, and would award it a strong B and a smiley face sticker. But a gold star? Probably not.

Such distinctions and awards are saved for alt-reality episodes produced by the likes of Friends. (Monica would appreciate the gold star I just mentioned in either reality — that I know.) Other strong performers in my book? Community, Supernatural, Buffy the Vampire Slayer, and The O.C. (I don’t count Fringe because that’s basically an alt-world SHOW. So it actually rules all the other alt-episodes in my TV kingdom.) I’d also give high marks to the Boy Meets World episode where Cory and Shawn imagined what it’d be like if they were never friends — but that’s mostly because I’ve referenced “Plays with Squirrels” so many times in my life that I’d feel like a fraud not to acknowledge it.

That’s just my take, readers. I want to know yours. Where would you rank the alt-reality episode of Grey’s? And which ones do you think top them all?

Read more:
‘Grey’s Anatomy’ recap: Bizarro Seattle Grace
What ‘What If?’ TV episodes would you like to see? 

Read more:
‘Grey’s Anatomy’ alt-reality episode: Where does it rank among the classics?

Posted in Anatomy | Tagged , , , , , , , , , , , , | Comments Off

The Pet Corner: Behold! The future of modern medicine is here

Do you remember when we used to think some things were impossible? Modern technology has taught us to never say never or impossible. I think about the 1970s and 1980s growing up without cell phones, computers and many of the electronically advanced gadgets that our kids today take for granted. I can’t even imagine what the great innovators will come up with next.

When I was a young child, I remember watching science fiction movies about cloning people and remember how obscure and unbelievable it seemed at the time. It was common knowledge that cloning was strictly science fiction. Now, cloning is not only possible, but a procedure that has occurred with astonishing success. Fortunately, cloning has only been performed with animals and not yet humans.

Medically speaking, one of the most popular and potentially one of the most substantial advances in modern medicine is stem cell research and therapy. Initially, stem cell research was met with a great deal of resistance and controversy. The reason stem cell research had trouble getting started was because stem cells could only be collected from fetuses. With time, scientists have successfully harvested stem cells from other sources.

Stem cells are primitive or extremely young cells which are capable of dividing and changing into a variety of cell types. They have the ability to develop into cells that form muscle, cartilage, bone or other tissues. One of the remarkable findings about stem cells is that they seem to detect and “know” which tissue is damaged and automatically change into the cells needing repaired.

In actuality, the damaged tissue sends some type of signal to the stem cells allowing them to respond and promote healing of the injured tissues. Essentially, stem cells have the ability to grow into mature tissue cells wherever they are needed and this makes them very useful for repairing certain body tissues damaged by injury, disease and possibly aging.

Stem cell treatment is a type of medical therapy called regenerative medicine. Regenerative medicine is simply a category of medical therapy pertaining to growing new tissue. Although stem cell therapy is an extremely unique and obviously beneficial type of medical treatment, it is also a very vast field of medical research and certainly has not been completely perfected. There are countless possibilities and applications for stem cell therapy and medical researchers have barely scratched the surface with regards to stem cell potential.

Until now the gold standard for treating arthritis in pets has been to give them anti-inflammatory medications, joint supplements and sometimes acupuncture. Over the years, these types of medications have improved greatly and pets have benefitted wonderfully from receiving this kind of treatment. However, even with the improvements, these medications have potential side effects. Sometimes, the side effects may even outweigh the benefits, depending on the individual circumstance.

Therefore, stem cell therapy offers treatment that doesn’t just relieve the symptoms, but actually regenerates or grows new tissue allowing for complete healing and without side effects. Presently, there are some stem cell applications already being used in veterinary medicine!

Recently, veterinary specialists have developed a technique for collecting stem cells from fat tissue and administering the stem cells into dogs, cats and horses specifically for treatment of arthritis. The process involves collecting a small amount of fat from the patient and then the fat is placed into a machine which extracts and concentrates stem cells. Next, the stem cells are injected back into the patient’s joints forthe treatment of arthritis.

There is a certain protocol for proceeding with the stem cell therapy. First, a definitive diagnosis of arthritis, using X-rays, must be made by your veterinarian. Additionally, your pet would need a complete workup including blood tests and additional X-rays to rule out any other disease processes such as infection or cancer. Any patient with cancer would not be a good candidate for stem cell therapy and any infection would need to be cleared prior to stem cell therapy.

Following the initial workup, your pet would be sedated or anesthetized for surgical collection of fat tissue. The fat tissue would then be sent to a lab to have the stem cells extracted and processed from the fat. Then, your pet would need to be sedated again to administer the injections containing the stem cells into their arthritic joints.

In pets, stem cell therapy is primarily available and being used for arthritis. However, I have no doubt that it won’t be long before stem cell therapy will be used in pets to treat many diseases and conditions. It has already shown to be effective for diabetes, allergies, gastrointestinal diseases, pancreatitis and many other diseases.

If you have a pet that you think might be suffering from arthritis, contact your veterinarian as soon as possible to consider stem cell therapy and to ensure your pet lives a long, healthy and happy life.

See the rest here:
The Pet Corner: Behold! The future of modern medicine is here

Posted in Cell Medicine | Tagged , , , , , , , | Comments Off

The promise of stem cell therapies forum

(SACRAMENTO, Calif.) – Experts from UC Davis Health System will share the latest research about regenerative medicine, with a focus on chronic pain and the promise of stem cell therapies, during a community forum on the university's Sacramento campus. The discussion takes place on Tuesday, Feb. 7, from 6- 7:30 p.m. at the UC Davis Education Building, 4610 X Street, in Sacramento.

The event features Jan Nolta, director of the UC Davis Institute for Regenerative Cures; Scott Fishman, chief of the UC Davis Division of Pain Medicine; and Kee Kim, chief of spinal neurosurgery at UC Davis Medical Center. The three specialists will discuss the challenges of treating chronic pain, especially back and neck pain, and the clinical research now under way to use stem cell therapies to overcome it.

The forum is free and open to the public. It is part of “Stem Cell Dialogues,” UC Davis Health System's discussion series about regenerative medicine and the goal of turning stem cells into cures. Each speaker will provide a short presentation followed by a panel discussion and question and answer period. The event will be moderated by Fred Meyers, professor of medicine and pathology, and executive associate dean of UC Davis School of Medicine.

Seating is limited. Those interested in attending must reserve a seat by contacting Kate Rodrigues at 916-734-9404 or e-mail kathleen.rodrigues@ucdmc.ucdavis.edu. Doors open at 5:30 p.m.  Free parking will be available in Lots 12 and 14, just south of the Education Building, near 45th Street and 2nd Avenue.

UC Davis is playing a leading role in regenerative medicine, with nearly 150 scientists working on a variety of stem cell-related research projects at campus locations in both Davis and Sacramento. The UC Davis Institute for Regenerative Cures, a facility supported by the California Institute for Regenerative Medicine (CIRM), opened in 2010 on the Sacramento campus. This $62 million facility is the university's hub for stem cell science. It includes Northern California's largest academic Good Manufacturing Practice laboratory, with state-of-the-art equipment and manufacturing rooms for cellular and gene therapies. UC Davis also has a Translational Human Embryonic Stem Cell Shared Research Facility in Davis and a collaborative partnership with the Institute for Pediatric Regenerative Medicine at Shriners Hospital for Children Northern California. All of the programs and facilities complement the university's Clinical and Translational Science Center, and focus on turning stem cells into cures. For more information, visit www.ucdmc.ucdavis.edu/stemcellresearch.

Original post:
The promise of stem cell therapies forum

Posted in Cell Medicine | Tagged , , , , , , , , , , | Comments Off

New era of medicine in the offing, says scientist

The Hindu Prof. Shinya Yamanaka of Centre for iPS Cell Research and Application, Japan, delivering a lecture in New Delhi on Friday. Photo: R.V.Moorthy

Renowned Japanese scientist Shinya Yamanaka, who achieved a major breakthrough in the emerging area of stem cell research by creating a possible alternative to embryonic stem cells in 2007, expressed confidence here on Friday that drugs would be available soon for diseases for which therapies are yet to be found.

Delivering a lecture on “New Era of Medicine with iPS Cells” organised jointly by Cell Press and TNQ Books and Journals, Prof. Yamanaka said the cells — “induced pluripotent stem cells [iPS Cells]'' — developed by him and his team would not only help overcome the ethical issues surrounding use of embryonic stem cells for treatment of diseases like spinal cord injuries, Type I diabetes or macular diseases but also help in development of drugs for conditions like motor neuron disease.

Embryonic stem cell therapy is considered important as it offers immense possibilities for treatment of a wide range of diseases and conditions since the cells proliferaterapidly and are pluripotent or possess the capability to differentiate into any type of cell, said Prof. Yamanaka. But it suffers from a major ethical issue as it involves use of live human embryos, Prof. Yamanaka pointed out. He said if there was a post-transplant rejection, they cannot be used from the patient's own cell.The iPS cells, on the other hand, are created from adult skin cells and do not have these two problems, while at the same time they provide for rapid proliferation and the possibility to differentiate into any type of cell, he said. Prof. Yamanaka and his team generated iPS mouse cells in 2006 and followed up with iPS cells developed from human skin cells in 2007.

Speaking about the potentials of iPS cells, he said studies using the cells for treatment of spinal cord injuries have already shown good results in mouse and monkey specimens and in two to three years scientists would be ready to go in for clinical trials. He, however, admitted that there are several challenges before the new technology. Its safety is yet to be proved completely and the process of deriving patient-specific iPS cells is time-consuming and expensive.

He expressed hope that scientists who are working on itwould overcome the challenges and a new era in medical treatment would emerge soon.

Union Human Resource Development Minister Kapil Sibal, who introduced him, said his Ministry along with the Ministries of Health and Science & Technology would take steps for Indian scientists to collaborate with him.

TNQ Books and Journals Managing Director Mariam Ram and Cell Press Executive Editor Emilie Marcus also spoke.

See original here:
New era of medicine in the offing, says scientist

Posted in Cell Medicine | Tagged , , , , , , , , , | Comments Off

Stem Cell Therapy in Neuromuscular Disease Research – Video


31-01-2012 15:24 MDA Vice President of Research Sanjay Bidichandani explains the promising research being done in neuromuscular disease research using adult stem cells.

View post:
Stem Cell Therapy in Neuromuscular Disease Research – Video

Posted in Stem Cell Therapy | Tagged , , , , , , , , , , | Comments Off

Opinion: No Objections to Nano?

While biotechnology has met with mixed public reactions, to date nanotechnology seems to invoke much less public concern.

Some forms of biotechnology have become notoriously controversial. Genetic modification of crops, for example, altered the food supply in ways some consumers found troublesome, either because of anticipated consequences, a lack of tangible benefit, lack of opportunity to participate in the decision-making, or simply a sense of inherent “unnaturalness.” Stem cell research has raised similar uneasiness, albeit for entirely different reasons, largely moral beliefs that equate it with the destruction of human embryos. So far, though, public perception of nanotechnology does not seem to be headed in the same direction. Sure, there are appeals for regulation and isolated protests, but it doesn’t seem as though there is really as much in the way of concerted will behind them. While some might be waiting for the other shoe to drop—I’ve been told many times that public concerns about nano are bound to emerge “just as soon as people understand what this is all about”—events so far suggest it may be a long wait.

Despite emerging evidence of potential toxicity to human health and the environment from some forms of nanotechnology under some circumstances, not much popular alarm has arisen. Great uncertainty remains over which products and under what circumstances we should be concerned, but of course this hasn’t stopped public reaction in the past. Several potential “triggering events” of the sort we social scientists might have expected would unleash underlying fears have already happened. In 2006, reports emerged of serious respiratory problems among German consumers using a household cleaning product called “Magic Nano,” and evidence published in 2009 indicated severe lung disease and even deaths among a small group of Chinese factory workers exposed to nanoparticles (and many other chemicals, as it turns out). In both cases, the link between nanotechnology and disease is far from clear. “Magic Nano” may not even have contained nanoparticles; the label was apparently chosen in an attempt to hype the product, much like the name “iPod nano.” Clearly, the marketers involved believed the word “nano” is attractive to consumers, rather than a source of concern for them.

To me, as a social scientist who studies risk communication, perception and reality are indeed the same thing, and so the interesting question is why, when uncertainty about risks has certainly not stopped public opinion from turning sour in the past, should nano be getting the benefit of the doubt while so much of bio remains persistently controversial?

The answer may lie in the nature of our technoscientific culture. I recently published a multi-year panel study involving 76 citizens of South Carolina, representing various walks of life, which reinforced the notion that because most Americans like technology, they are generally willing to give nanotechnology a pass, at least for now, even though they don’t know much about it. About two-thirds of the panel held positive views, and the negative minority seemed to draw on negative expectations about technology more generally, rather than specific views about nanotechnology. Panelists’ views changed little over the 32 months of the study. The most common concerns, reasonably enough, centered on unexpected consequences and unanticipated side effects. Indeed, people seemed perfectly aware of the uncertainties surrounding nano-associated risks, but this hardly appeared to induce fear.

To those of us who lived through the early years of the genetically modified (GM) food “wars,” which some tended to attribute to a lack of familiarity alongside low levels of trust, this is pretty interesting. Nano involves many of the same sorts of key actors (major corporations, government regulators, scientists, engineers, and consumer advocacy groups) and, if anything, even greater levels of scientific uncertainty. Yet there’s something quite different about what we call the “climate of public opinion” for nanotechnology as opposed to biotechnology, particularly GM. To be sure, some observers are invoking the so-called precautionary principle (the largely European idea that we should not adopt a technology until the evidence shows it does not cause harm), but even in such cases it usually seems that they are calling for precaution because they think this is generally the right way to manage any new technology, rather than because nanotechnology is particularly worrisome.

So what makes nano so different from bio? Simply put, manipulating DNA simply seems to challenge our underlying cultural ideas about how the world ought to be in ways that manipulating otherwise ordinary materials does not.

For those who want to communicate about risk in a responsible way with the so-called “lay” or non-specialist public, nano represents a novel challenge. Rather than being an “amplified” risk, by which I mean one that the media and other social institutions have tended to highlight, nanotechnology may represent an “attenuated” risk, or one that these institutions have tended to ignore. If people are too fearful of a technology, they may lose out on its potential benefits, yet if too trusting, they may ignore important risks. But few among us really want to be the one yelling “Fire!” in a crowded world. After all, we’re still not even sure there’s a problem. Are we?

Indeed, just last month (January 25), the National Research Council issued a report calling for a coordinated research plan to investigate nanotechnology’s poorly understood risks to both health and environment, lest its beneficial promise for society ultimately go unrealized.

Susanna Priest (susannapriest@yahoo.com) is the author of Nanotechnology and the Public: Risk Perception and Risk Communication (Taylor and Francis, 2012), as well as a November 2011 article in Risk Analysis (Volume 31, Issue 11, pp. 1718-1733) on “Envisioning Emerging Technologies,” which reports on the panel study results as part of a special issue. She also edits the academic journal Science Communication.

More here:
Opinion: No Objections to Nano?

Posted in Nanotechnology | Tagged , , , , , , , | Comments Off

Molecular subtypes of lung cancer manifest as different diseases

Different kinds of lung cancer behave in different ways, suggesting they are fundamentally different diseases. According to a University of Colorado Cancer Center study published in Cancer, the official journal of the American Cancer Society, different subgroups of non-small cell lung cancer (NSCLC) show distinct patterns of spread in the body.

Continue reading here:
Molecular subtypes of lung cancer manifest as different diseases

Posted in Molecular Medicine | Tagged , , , , , , , , , , , , , , | Comments Off

SAFE-BioPharma® Standard to be Highlighted at Molecular TriCon

FORT LEE, N.J.–(BUSINESS WIRE)–

The role of SAFE-BioPharma interoperable digital identities in assuring secure cloud computing will be featured at Cambridge Healthtech Institute's Molecular Medicine Tri-Conference, Sunday, February 19, at Moscone Center in San Francisco. The Molecular Medicine Tri-Conference is one of the key life science industry meetings covering the latest trends, technologies, research breakthroughs, regulatory issues, and best practice examples of molecular and translational medicine advances.

Three afternoon presentations are scheduled under the title, Cloud Computing and Governance. They are:

1:30 An Expert's Guide through the Identity Landscape
Rich Furr, Head, Global Regulatory Affairs and Chief Compliance Officer, SAFE-BioPharma Association. Overview of US and EU government and industry-driven identity management initiatives to develop a trusted internet identity capability community.

2:00 Research Collaboration in the Cloud: How NCI and Research Partners are Using Interoperable Digital Identities, Digital Signatures, and Cloud Computing to Accelerate Drug Development
Steven Friedman, MHSA, Chief, Clinical Trials Operations and Informatics Branch, Cancer Therapy Evaluation Program, National Cancer Institute. Discussion of recent pilot study involving government (NCI) and industry (Bristol-Myers Squibb, sanofi-aventis) cancer researchers showing how use of interoperable digital identities, digital signatures and cloud computing accelerates initiation of a clinical trial while lowering its costs.

2:30 The Role of a Standard-Based Interoperable Digital Identity in Unlocking the Cloud
Mollie Shields-Uehling, President & CEO, SAFE-BioPharma Association. Presentation on challenges associated with the use of cloud computing in clinical trials including managing secure access, true authentication of user’s identity, and ability to apply legally binding digital signatures to electronic documents across broad range of global participants.

For more information of the Molecular Medicine Tri-Conference visit http://www.triconference.com/mmtc_homepage.aspx. For more information on the SAFE-BioPharma standard for digital identity and digital signatures used in life science and healthcare settings, visit http://www.safe-biopharma.org.

SAFE-BioPharma® is a trademark of SAFE-BioPharma Association. Any use of this trademark requires approval from SAFE-BioPharma Association.

Go here to read the rest:
SAFE-BioPharma® Standard to be Highlighted at Molecular TriCon

Posted in Molecular Medicine | Tagged , , , , , , , , , , , | Comments Off